v3.25.3
Revenues (Tables)
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Product revenue - gross127,103 107,678 355,965 307,401 
Less: Rebates and sales returns(11,742)(5,831)(25,870)(18,299)
Product revenue - net115,361 101,847 330,095 289,102 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
ZEJULA42,432 48,227 133,002 138,727 
VYVGART / VYVGART Hytrulo27,727 27,265 72,329 63,617 
NUZYRA15,430 9,997 44,840 32,205 
OPTUNE12,657 7,715 36,375 32,779 
QINLOCK8,901 8,643 25,946 21,774 
XACDURO6,445 — 12,184 — 
AUGTYRO1,677 — 4,702 — 
Other (i)92 — 717 — 
Product revenue - net115,361 101,847 330,095 289,102 
(i)Other includes product candidates sold in patient programs prior to commercialization.